Neurol. praxi 2020; 21(Suppl.C): 3-10 | DOI: 10.36290/neu.2021.007
In the recent years, we have witnessed a huge increase in treatment options for multiple sclerosis (MS) with various mechanisms of actions that affect the immune system by immunomodulation or immunosuppression. With the advent of new drugs with higher efficacy than we know in interferons-beta or glatiramer acetate, the management of the patient´s treatment with MS with regard to its safety, including the prevention of infections, which can significantly complicate the course of MS. The correct indication of the selected products of the new drugs generation, as well as monitoring of treatment with the chosen medical drug often requires broad multidisciplinary...